Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women

By Comen E.   Davids M.   Kirchhoff T.   Hudis C.   Offit K.   Robson M.  

Breast Cancer Research and Treatment, Vol. 129, Iss. 1, 2011-08 ,pp. : 185-190

Springer Publishing Company

Access to resources Recommend Favorite

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations

By Bayraktar Soley  

Breast Cancer Research and Treatment, Vol. 130, Iss. 1, 2011-11 ,pp. : 145-153

Springer Publishing Company

Access to resources Recommend Favorite

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells

By Arun Banu   Akar Ugur   Gutierrez-Barrera Angelica M.   Hortobagyi Gabriel N.   Ozpolat Bulent  

International Journal of Oncology, Vol. 47, Iss. 1, 2015-07 ,pp. : 262-268

Spandidos Publications

Access to resources Recommend Favorite

Novel BRCA1 deleterious mutation (c.1949_1950delTA) in a woman of Senegalese descent with triple-negative early-onset breast cancer

By                  

Oncology Letters, Vol. 2, Iss. 6, 2011-01 ,pp. : 1287-1289

Spandidos Publications

Access to resources Recommend Favorite

BRCA1 and BRCA2 in breast cancer

By Yang X.   Lippman M.E.  

Breast Cancer Research and Treatment, Vol. 54, Iss. 1, 1999-03 ,pp. : 1-10

Springer Publishing Company

Access to resources Recommend Favorite